ABL1 and leukemia: Indeed, the identification of HLA class I [17], and HLA class II- binding [18] BCR-ABL peptides supports the hypothesis that antigen presentation, and subsequent T cell recognition of this specific oncoprotein may serve as a mechanism for the graft versus leukemia (GVL) effect commonly seen in bone marrow transplant patients.